| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 14 | 2025 | 549 | 2.920 |
Why?
|
| Breast Neoplasms | 23 | 2025 | 2682 | 2.680 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 816 | 1.400 |
Why?
|
| Trastuzumab | 9 | 2025 | 154 | 0.990 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1347 | 0.890 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 28 | 0.820 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 127 | 0.810 |
Why?
|
| NF-kappa B | 6 | 2011 | 454 | 0.800 |
Why?
|
| Curcumin | 3 | 2011 | 43 | 0.770 |
Why?
|
| Azadirachta | 2 | 2011 | 3 | 0.720 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 2064 | 0.710 |
Why?
|
| Signal Transduction | 16 | 2025 | 4725 | 0.700 |
Why?
|
| Estrogen Receptor alpha | 5 | 2025 | 439 | 0.650 |
Why?
|
| Plant Extracts | 2 | 2011 | 135 | 0.640 |
Why?
|
| Neuroblastoma | 4 | 2011 | 550 | 0.590 |
Why?
|
| Apoptosis | 6 | 2019 | 1904 | 0.580 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 400 | 0.540 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 608 | 0.520 |
Why?
|
| Gamma Rays | 3 | 2011 | 42 | 0.520 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1828 | 0.520 |
Why?
|
| Gene Fusion | 1 | 2016 | 60 | 0.490 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 1683 | 0.470 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 42 | 0.430 |
Why?
|
| Carrier Proteins | 2 | 2020 | 1050 | 0.410 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2025 | 84 | 0.410 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3698 | 0.400 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 328 | 0.380 |
Why?
|
| Rosaceae | 1 | 2011 | 1 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 402 | 0.360 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 54 | 0.360 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 104 | 0.350 |
Why?
|
| Quinazolines | 3 | 2023 | 187 | 0.340 |
Why?
|
| Mice, Nude | 5 | 2025 | 757 | 0.340 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 176 | 0.340 |
Why?
|
| Digestive System | 1 | 2010 | 65 | 0.330 |
Why?
|
| Genes, p53 | 1 | 2010 | 222 | 0.320 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 741 | 0.310 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 116 | 0.310 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 1879 | 0.300 |
Why?
|
| Gene Amplification | 3 | 2019 | 240 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 234 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 666 | 0.290 |
Why?
|
| Genomics | 1 | 2016 | 1651 | 0.280 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 688 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 343 | 0.250 |
Why?
|
| Female | 23 | 2025 | 70664 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 727 | 0.230 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 61 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2016 | 331 | 0.220 |
Why?
|
| Humans | 30 | 2025 | 132083 | 0.220 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 383 | 0.220 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 155 | 0.220 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 68 | 0.200 |
Why?
|
| Cell Survival | 4 | 2021 | 869 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 303 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2025 | 359 | 0.180 |
Why?
|
| Prognosis | 5 | 2021 | 5006 | 0.180 |
Why?
|
| Remission Induction | 2 | 2020 | 307 | 0.180 |
Why?
|
| Mice | 10 | 2025 | 18565 | 0.180 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 9 | 0.180 |
Why?
|
| Plant Leaves | 2 | 2011 | 55 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 1411 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 64 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2020 | 60 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 998 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 130 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 20 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 231 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 249 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 265 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 255 | 0.150 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 142 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 99 | 0.150 |
Why?
|
| Brain | 1 | 2010 | 3201 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 365 | 0.140 |
Why?
|
| Animals | 10 | 2025 | 34951 | 0.140 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 201 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 775 | 0.140 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 1425 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2019 | 359 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 605 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 691 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 1564 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 1047 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 248 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 503 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 118 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2512 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 219 | 0.110 |
Why?
|
| Cell Separation | 1 | 2014 | 227 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 64 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1672 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5399 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 295 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 663 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1997 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2023 | 13014 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 806 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 20 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2011 | 34 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 10 | 0.090 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 33 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 39 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 403 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1367 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 6445 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 945 | 0.090 |
Why?
|
| Infrared Rays | 1 | 2010 | 23 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 891 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 71 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 623 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2011 | 295 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1803 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 234 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 180 | 0.080 |
Why?
|
| Telomerase | 1 | 2011 | 168 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 637 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 999 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 430 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 4541 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 354 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1292 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2679 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 217 | 0.070 |
Why?
|
| Mutation | 3 | 2025 | 6248 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1554 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1295 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 1613 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 2902 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 764 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1483 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 799 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2025 | 39 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1441 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3358 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 72 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 558 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 1366 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1017 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 880 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4764 | 0.040 |
Why?
|
| Middle Aged | 4 | 2025 | 28922 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 92 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 50 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 94 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 89 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 84 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 399 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 216 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 309 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 167 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2009 | 146 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 396 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 199 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 488 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 435 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1569 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 240 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 161 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 611 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 513 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3020 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 58 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 21404 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 243 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 296 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4694 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1332 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 11 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1724 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 46 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 31544 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 7119 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 258 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 701 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 1294 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 377 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9935 | 0.010 |
Why?
|